Clinical trials
Phase 1/2 Leukemia, Myeloid, Acute trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2016 | 5 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Terminated | 11 |
| Recruiting | 9 |
| Active, not recruiting | 5 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 4 |
| Novartis Pharmaceuticals | 3 |
| AbbVie | 2 |
| Celgene | 2 |
| Hoffmann-La Roche | 2 |
| Institut de Recherches Internationales Servier | 2 |
| AB Science | 1 |
| Acute Leukemia French Association | 1 |
| Advanced BioDesign | 1 |
| Advesya SAS | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 48 |
| Myelodysplastic Syndromes | 14 |
| Recurrence | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Leukemia | 7 |
| Hematologic Neoplasms | 6 |
| Leukemia, Myelomonocytic, Chronic | 4 |
| Multiple Myeloma | 4 |
| Neoplasms | 4 |
| Leukemia, Biphenotypic, Acute | 2 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.